E-mail

E-mail a Wiley Online Library Link

Wichit Arpornwirat, Istvan Albert, Vincent L. Hansen, Jeremey Levin, Rajesh R. Bandekar and Steven M. Grunberg Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy Cancer 115

Version of Record online: 15 OCT 2009 | DOI: 10.1002/cncr.24630

The addition of different dose regimens of the neurokinin-1 receptor antagonist casopitant to standard ondansetron/dexamethasone antiemetic prophylaxis increased the proportion of patients that achieved a complete response over the first 5 days after moderately emetogenic chemotherapy.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH